Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity

Author： Nigro Stefanie C.   Luon Darren   Baker William L.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.7, 2013-07, pp. : 839-848

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serotonin (5‐HT)2A/2C receptor agonist (2,5‐dimethoxy‐4‐idophenyl)‐2‐aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat

By  

BJU INTERNATIONAL, Vol. 116, Iss. 1, 2015-07 ,pp. : 147-155

John Wiley & Sons Inc

Access to resources Recommend Favorite

Indacaterol, a novel inhaled, once-daily, long-acting beta 2 -agonist for the treatment of obstructive airways diseases

By Beeh Kai  

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 691-699

Springer Publishing Company

Access to resources Recommend Favorite

Anti‐obesity and metabolic efficacy of the β3‐adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°C

By  

OBESITY, Vol. 23, Iss. 7, 2015-07 ,pp. : 1450-1459

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment intensification in type 2 diabetes mellitus and obesity

By Zawiejska Agnieszka   McAleese Jane   Yemparala Prasad   Taheri Shahrad  

British Journal of General Practice, Vol. 63, Iss. 609, 2013-04 ,pp. : 182-182

Royal College of General Practitioners

Access to resources Recommend Favorite

Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12‐Week Treatment: A Randomized Substudy

By  

OBESITY, Vol. 26, Iss. 2, 2018-02 ,pp. : 332-339

John Wiley & Sons Inc

Access to resources Recommend Favorite